Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp WT (NQ: LEXXW )

0.8000 UNCHANGED
Streaming Delayed Price Updated: 12:12 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp WT

< Previous 1 2 3 4 5 6 7 Next >
Lexaria Granted Two New Patents in Canada
Via ACCESSWIRE
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Via ACCESSWIRE
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
Via ACCESSWIRE
Lexaria Receives New Patents
Via ACCESSWIRE
Lexaria Appoints New Chief Financial Officer
Via ACCESSWIRE
Lexaria Provides Update on Investigational New Drug Application Progress
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
Via ACCESSWIRE
Lexaria Announces 2023 Annual Meeting Results
Via ACCESSWIRE
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
Via ACCESSWIRE
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
Via ACCESSWIRE
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Via ACCESSWIRE
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
Via ACCESSWIRE
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
Via Benzinga
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
Via ACCESSWIRE
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
Via ACCESSWIRE
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
Via ACCESSWIRE
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
Via ACCESSWIRE
Lexaria is Receiving Four New Patents
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.